Journal of Affective Disorders Reports (Jul 2023)

Efficacy of virtually-delivered Qigong/Tai Chi for depression in middle- and older-age adults with bipolar disorder (QT-BD): A pilot randomized controlled trial during the COVID-19 pandemic

  • Haley Park,
  • Christina Rigas,
  • Marim Ibrahim,
  • Chien-Lin Su,
  • Lisa Eyler,
  • Zoe Thomas,
  • Marouane Nassim,
  • Serge Beaulieu,
  • Gabriella Buck,
  • Soham Rej

Journal volume & issue
Vol. 13
p. 100604

Abstract

Read online

Background: Depressive symptoms in middle-aged and older age bipolar disorder (BD) are associated with decreased quality of life and premature mortality. Yet, currently available pharmacological treatments are limited in efficacy. Mind-body interventions have been shown to improve mood, quality of life, and cognition in other adult populations, and may thus provide a promising therapeutic alternative. Here we conduct the first randomized controlled trial (RCT) examining the efficacy of a group Qigong/Tai Chi intervention (QT-BD) for reducing depressive symptoms in middle-aged and older adults with BD. As a further innovation during the COVID pandemic, we used Zoom to deliver the group intervention and active control. Methods: We conducted a virtually-delivered 12-week pilot RCT with 23 patients with BD aged >= 40 comparing a QT-BD intervention versus an active control (light exercise). We assessed depressive symptoms (primary outcome), verbal fluency (secondary outcome), and functioning/quality of life (exploratory outcomes) at baseline and 12-weeks. Results: No statistically significant differences were observed between groups for all outcomes (all p's>0.05). However, non-significant decreases in depressive symptoms were found in the subgroup of participants with baseline MADRS scores ≥10 in the QT-BD intervention only (p = 0.07). Limitations: Our sample size was limited and the virtually-delivered format may have limited the positive benefits of face-to-face interventions. Conclusions: This novel pilot study suggests that QT-BD may be a feasible and efficacious intervention for reducing depressive symptoms in middle- and older-aged BD, particularly when baseline MADRS is ≥10, warranting further investigation in larger-scale trials.

Keywords